Our mission is to develop affordable cell- and gene-based therapies with better efficacy to help patients fight against cancers and achieve long-term remission.

Our vision is to lead the industry of cell and gene therapy in both China and worldwide and advance the current cancer treatment guidelines by pushing CAR-T cell therapy from last line to 2nd line of cancer treatments by reasons of affordability, better safety and efficacy, least side effect, and long-term remission.

As a cutting-edge medical research institute in immunotherapy and gene therapy trials in China, GIMI has registered more than 40 clinical trials in ClinicalTrials.gov. The multi-center trial hospitals include Aero Space Center Hospital (ASCH, Beijing), Beijing Jingdu Children’s Hospital, Beijing Puhua International Hospital, Zhujiang Hospital of Southern Medical University (Guangzhou), Peking University Shenzhen Hospital, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen Hospital of Southern Medical University, etc.

GIMI has arranged CAR-T technology alliance with Nagoya University Hospital in Japan, Siriraj Hospital of Mahidol University in Thailand and National Research Center for Hematology in Russia to prove the affordability of CAR-T cell therapy with better efficacy.

GIMI has annually presented its amazing clinical trial data and results in the American Society of Hematology (ASH) Annual Meetings since 2014 through 2022.

For any inquiry, please contact GIMI at c@szgimi.org.